ERBB2 and breast cancer: Of note, even large molecules (e.g., T-DM1, 89Zr-trastuzumab) were reported to penetrate HER2-positive breast cancer brain metastases [7, 19] due to local disruption of the blood-brain barrier at these sites [20].